Effects of interleukin-1 antagonism and corticosteroids on fibroblast growth factor-21 in patients with metabolic syndrome

Effects of interleukin-1 antagonism and corticosteroids on fibroblast growth factor-21 in patients with metabolic syndrome

Abstract Fibroblast growth factor-21 (FGF21) is elevated in patients with the metabolic syndrome. Although the exact underlying mechanisms remain ill-defined, chronic low-grade inflammation with increased Interleukin-(IL)-1β expression may be responsible. The aim of this study was to investigate eff...

Full description

Bibliographic Details
Main Authors: Fahim Ebrahimi, Sandrine Andrea Urwyler, Matthias Johannes Betz, Emanuel Remigius Christ, Philipp Schuetz, Beat Mueller, Marc Yves Donath, Mirjam Christ-Crain
Format: Article
Language:English
Published: Nature Portfolio 2021-04-01
Series:Scientific Reports
Online Access:https://doi.org/10.1038/s41598-021-87207-w

Internet

https://doi.org/10.1038/s41598-021-87207-w

Similar Items